Rezatapopt and the TP53 Y220C Mutation: A New Frontier in Precision Oncology
Cancer research is moving quickly, and sometimes a scientific breakthrough opens the door to a new type of targeted treatment.¹ One exciting area of research focuses on a drug called rezatapopt, an emerging p53-targeted therapy designed to treat cancers with a specific mutation in the TP53 gene known as TP53 Y220C.² Early laboratory and clinical research suggests that this therapy may help restore the natural tumor-fighting ability of the p53 protein in certain cancers.³ This blog explains what the TP53 Y220C mutation is, how rezatapopt works as a targeted therapy, and why researchers are watching this therapy closely.
The Importance of p53 — the “Guardian of the Genome”
The TP53 gene produces the p53 protein, which is often called the *“guardian of the genome.”⁴ This protein helps prevent cancer by repairing damaged DNA or triggering the death of abnormal cells.⁴ Unfortunately, TP53 is the most frequently mutated gene in human cancer, with mutations occurring in roughly half of all cancers.⁵ When TP53 is altered, the p53 protein may lose its ability to control cell growth and DNA repair.⁵ When p53 stops working properly, damaged cells can multiply and form tumors. For many years, scientists considered TP53 mutations “undruggable.” Designing medicines that could repair a defective protein proved extremely difficult. However, advances in structural biology and drug design have begun to change this perspective and have led to new mutation-specific therapies targeting p53.³
Understanding the TP53 Y220C Mutation
One particular TP53 mutation, TP53 Y220C, occurs in roughly 1% of all solid tumors.³ Although that percentage may seem small, it still affects thousands of patients worldwide each year and represents an important opportunity for precision oncology drug development. The mutation causes a structural change in the p53 protein that creates a small pocket on the surface of the protein.³ This structural change destabilizes the protein, making it fold incorrectly and preventing it from performing its tumor-suppressing function.³ Researchers realized that this structural pocket might actually create a therapeutic opportunity. If a drug could fit into this pocket, it might stabilize the protein and restore its normal function. This insight led to the development of rezatapopt (PC14586).³
How Rezatapopt Works
Rezatapopt is a first-in-class small-molecule therapy designed specifically for the TP53 Y220C mutation.³ The drug binds directly into the pocket created by the Y220C mutation and stabilizes the p53 protein.³ By restoring the protein’s structure, rezatapopt can help p53 regain its ability to activate genes that slow cell growth or trigger cancer cell death.³ In laboratory studies and preclinical models, the drug demonstrated the ability to reactivate tumor-suppressor signaling and inhibit tumor growth in cancers carrying the TP53 Y220C mutation.³
Early Clinical Results: Phase 1 Trial Findings
The first clinical evidence supporting this approach comes from an early-phase study evaluating rezatapopt in patients with advanced solid tumors containing the TP53 Y220C mutation.⁶ Results from the Phase 1 trial published in the New England Journal of Medicine showed encouraging early signals of activity in heavily pretreated patients.⁶ In the study, patients received rezatapopt orally in 21-day cycles, and researchers evaluated safety, tumor responses, and durability of treatment benefit.⁶ Among patients treated at the recommended dose, objective tumor responses were observed in approximately one-third of patients, including individuals with ovarian, breast, and other cancers harboring the TP53 Y220C mutation.⁶ Several additional patients experienced disease stabilization, meaning the cancer stopped growing for a period of time.⁶ Importantly, responses appeared to be durable in some patients, lasting many months after treatment began.⁶ The treatment was generally manageable from a safety perspective, with most side effects considered mild to moderate.⁶ These early results represent one of the first demonstrations that a drug designed to restore the function of a specific p53 mutation may produce clinical responses in patients.⁶
Ongoing Clinical Trials: The PYNNACLE Study
Following these early results, rezatapopt continues to be studied in clinical trials. One of the most important studies underway is the PYNNACLE Phase II clinical trial, which is evaluating the drug in several cancer types containing the TP53 Y220C mutation.⁷ The study is enrolling patients with advanced cancers such as: ovarian cancer, breast cancer, lung cancer, and endometrial cancer. Participants take rezatapopt orally once daily in repeating 21-day cycles.⁷ Researchers are evaluating several outcomes, including: tumor response rates, duration of response, progression-free survival, overall survival, and safety and side effects. Because this is a mutation-specific therapy, patients must first undergo molecular testing to confirm the presence of the TP53 Y220C mutation.
Why This Research Matters
Targeting TP53 mutations has been one of the most difficult challenges in cancer research. For decades, scientists believed that repairing a tumor-suppressor protein might not be possible with drug therapy. If therapies like rezatapopt continue to show success, they could open an entirely new category of cancer treatments: medicines that restore the function of damaged tumor-suppressor proteins rather than simply blocking cancer growth signals.³ This approach represents a powerful example of precision oncology, where treatments are matched to the specific molecular features of a patient’s cancer.
What This Means for Patients
The development of drugs like rezatapopt highlights why comprehensive molecular profiling of tumors is so important in modern cancer care. Without genomic testing, many patients would never know whether their cancer contains mutations that could qualify them for targeted therapies or clinical trials. Because TP53 mutations occur across many cancer types, therapies targeting specific mutations like Y220C may ultimately benefit patients with several different cancers that share the same molecular driver.
How Navexio Helps Patients Navigate Emerging Therapies
New targeted therapies are emerging rapidly, and it can be difficult for patients and families to keep track of what may apply to their specific cancer. At Navexio, our team helps patients and caregivers understand the molecular profile of their cancer and identify testing, treatment options, and clinical trials that may be relevant to them. Our Molecular & Genomic Check-Up reviews pathology and genomic testing to identify whether important biomarkers may have been missed. When appropriate, we also help patients explore clinical trials investigating emerging precision oncology therapies such as rezatapopt for TP53 Y220C-mutant cancers. As cancer care becomes increasingly personalized, understanding the molecular drivers of a tumor is often the key to unlocking new treatment opportunities. At Navexio, our mission is simple: leave no stone unturned in the search for the best possible path forward for every patient.
References:
Zhao S et al. p53: a player in the tumor microenvironment. Oncol Res. 2025. (LINK)
Ma Z et al. Rezatapopt (PC14586): a first-in-class p53 Y220C stabilizer. J Med Chem. 2025. (LINK)
Vu BT et al. Discovery of rezatapopt (PC14586). ACS Med Chem Lett. 2025. (LINK)
Lane DP. Cancer. p53, guardian of the genome. Nature. 1992. (LINK)
Tornsello LM. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review). Int J Mol Med. 2025. (LINK)
Schram AM, et al. Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors. New England Journal of Medicine. 2025. (LINK)
Schram AM, et al. PYNNACLE phase II trial of rezatapopt in TP53 Y220C-mutant cancers. Future Oncology. 2025. (LINK)